Stacey Stein
Medical Oncology Director for Hepatobiliary Cancer, RWJBarnabas Health · Rutgers Health
Credentials: · · · ·
History
- Present
- 2010–2012
- 2007–2010
Internal Medicine
Research
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 829 citations
The Lancet Oncology · 2020 · 467 citations
NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017
Journal of the National Comprehensive Cancer Network · 2017 · 279 citations
21 papers
12 papers
12 papers
11 papers
10 papers
8 papers · 7 as a resident
- CS
7 papers · 1 as a resident
6 papers
Clinical trials
- 2017–2019
Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer
Principal investigator · Completed · Phase 2
Yale University
- 2017–2018
Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer
Principal investigator · Withdrawn · Phase 1
Yale University
- 2014–2018
Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction
Principal investigator · Completed · Phase 1
Yale University